Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 8/20 | 0.67 |
| ▸ | MAPT | P10636 | 8/20 | 0.67 |
| ▸ | CYP3A4 | P08684 | 7/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.67 |
| ▸ | HPGD | P15428 | 6/20 | 0.67 |
| ▸ | MEN1 | O00255 | 6/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.67 |
| ▸ | TDP1 | Q9NUW8 | 6/20 | 0.67 |
| ▸ | AR | P10275 | 5/20 | 0.67 |
| ▸ | IP6K2 | Q9UHH9 | 5/20 | 0.67 |
| ▸ | CYP1A1 | P04798 | 5/20 | 0.67 |
| ▸ | CYP1B1 | Q16678 | 5/20 | 0.67 |
| ▸ | FTO | Q9C0B1 | 5/20 | 0.67 |
| ▸ | CYP19A1 | P11511 | 5/20 | 0.67 |
| ▸ | MAOB | P27338 | 5/20 | 0.67 |
| ▸ | NPC1 | O15118 | 5/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.67 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.67 |
| ▸ | GABRP | O00591 | 4/20 | 0.67 |
| ▸ | GABRD | O14764 | 4/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL157490 | 0.80 | AR (1.00) | KMT2AMAPTCYP3A4SMN1; SMN2HPGD | |
| Apigenin SCHEMBL29351464 | 0.80 | KMT2A (1.00) | KMT2AMAPTCYP3A4SMN1; SMN2HPGD | |
| Apigenin SCHEMBL19428 | 0.80 | KMT2A (1.00) | KMT2AMAPTCYP3A4SMN1; SMN2HPGD | |
| Apigenin SCHEMBL5083245 | 0.80 | KMT2A (1.00) | KMT2AMAPTCYP3A4SMN1; SMN2HPGD | |
| SCHEMBL824463 | 0.79 | KMT2A (0.76) | KMT2AMAPTCYP3A4SMN1; SMN2HPGD | |
| Apigenin SCHEMBL31477961 | 0.79 | KMT2A (0.97) | KMT2AMAPTCYP3A4SMN1; SMN2HPGD | |
| Apigenin SCHEMBL31168790 | 0.79 | KMT2A (0.97) | KMT2AMAPTCYP3A4SMN1; SMN2HPGD | |
| Apigenin SCHEMBL29448148 | 0.79 | KMT2A (0.97) | KMT2AMAPTCYP3A4SMN1; SMN2HPGD | |
| Apigenin SCHEMBL29458838 | 0.79 | KMT2A (0.97) | KMT2AMAPTCYP3A4SMN1; SMN2HPGD | |
| Apigenin SCHEMBL30544810 | 0.79 | KMT2A (0.97) | KMT2AMAPTCYP3A4SMN1; SMN2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8242130-B2 | Flavanoids and isoflavanoids for the prevention and treatment of cardiovascular diseases | RESVERLOGIX CORP. (CA) | 2012-08-14 | — | — | US | disclosed |
| EP-1838296-B1 | FLAVANOIDS AND ISOFLAVANOIDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES | RESVERLOGIX CORP (CA) | 2012-08-08 | — | — | EP | disclosed |
| US-8093273-B2 | Flavanoids and isoflavanoids for the prevention and treatment of cardiovascular diseases | RESVERLOGIX CORP. (CA) | 2012-01-10 | — | — | US | disclosed |
| EP-2332527-A2 | Flavanoids and Isoflavanoids for the prevention and treatment of cardiovascular diseases | RESVERLOGIX CORP. (CA) | 2011-06-15 | — | — | EP | disclosed |
| US-20090259048-A1 | FLAVANOIDS AND ISOFLAVANOIDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES | RESVERLOGIX CORP. (CA) | 2009-10-15 | — | — | US | disclosed |
| EP-1838296-A2 | FLAVANOIDS AND ISOFLAVANOIDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES | RESVERLOGIX CORP. (CA) | 2007-10-03 | — | — | EP | disclosed |
| US-20060205767-A1 | Flavanoids and isoflavanoids for the prevention and treatment of cardiovascular diseases | HEPALINK (HONG KONG) LIMITED (HK) | 2006-09-14 | — | — | US | disclosed |
| WO-2006045096-A2 | FLAVANOIDS AND ISOFLAVANOIDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES | RESVERLOGIX CORP. (CA) | 2006-04-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060205767-A1 | Flavanoids and isoflavanoids for the prevention and treatment of cardiovascular diseases | APOB, APOL1, FABP3 | KMT2A 2842/4885MAPT 2914/4885CYP3A4 1730/4885 |
| US-20090259048-A1 | FLAVANOIDS AND ISOFLAVANOIDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES | APOB, APOL1, FABP3 | KMT2A 2842/4885MAPT 2914/4885CYP3A4 1730/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.